Byoung Geol Choi

Sep 1, 2024 | radcliffecardiology.com | Gi-Byoung Nam |Harriette Van Spall |Manesh R. Patel |Byoung Geol Choi

ESC Congress 2024 — OCEANIC-AF was halted early due to a lack of efficacy in 2023. Investigators shared details of the trial at ESC, comparing asundexian against apixaban in patients with atrial fibrillation at risk of stroke. Host Dr Harriette Van Spall (McMaster University, Hamilton, Canada) sits down with primary investigator Dr Manesh R Patel (Duke University Health System, USA) to discuss the much-anticipated data from the OCEANIC-AF trial (NCT05643573; Bayer).